Bugs to Drugs – The Evolution of a Biotech Company

Friday, April 5 2013
12:30 pm – 2:30 pm

Location: Cummings Center, Beverly, #100 Building – Room 221E Conference Center

Dr. Todd Milne, an Ironwood Pharmaceuticals founder and current vice president of biology, will speak about the company evolution from founding concept to first commercial product and the challenges and promise for the future.  Started in January 1998, Ironwood Pharmaceuticals (nee Microbia) has grown and evolved from 4 post docs at the Whitehead Institute to a 550 person organization that is discovering, developing, and commercializing innovative medicines.

Refreshments Served:   Pizza, salads, and soft-drinks

Cost for Members and Non members,

  • Thanks to our host there is no charge for NSTC Members and Affiliates
  • $10.00 for Non-Members

Pre-register at http://www.nstc.org

For more information, email FirstFridayBiosci@nstc.org

Host:   PCI Synthesis is a 14-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products. A contract manufacturing organization (CMO), PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules and APIs used in generic pharmaceuticals. To learn more about PCI Synthesis, its proprietary NCE development activities and process R&D capabilities please visit www.pcisynthesis.com.


Share MassBio